ENScientists at ActiTrexx GmbH, a Mainz-based biotechnology spin-off, in close collaboration with Universitätsmedizin Mainz and partner institutions in Dresden, Münster, and Dortmund, have completed a first-in-human clinical trial evaluating activated regulatory T cells to prevent severe transplant complications. The novel cellular therapeutic product, designated as ATreg or Actileucel, is manufactured from white blood cells isolated from healthy blood donors and administered after a rapid activation process. Designed to prevent acute graft-versus-host disease following allogeneic stem cell transplantation, the therapy demonstrated that activated regulatory cells can be produced within 24 hours and delivered safely to patients. Results from the Phase I/II study confirmed that the infusion is well tolerated and structurally feasible in a clinical setting.
The Challenge of Graft-versus-Host Disease in Allogeneic Stem Cell Therapy
Allogeneic stem cell transplantation remains one of the primary curative treatment options for patients diagnosed with life-threatening hematological malignancies, including acute leukemias, aggressive lymphomas, and severe bone marrow disorders. During this intensive procedure, hematopoietic stem cells harvested from a genetically matched donor are infused into the patient to restore healthy blood cell production. The newly established donor immune system plays a crucial role in eliminating residual malignant cells through a beneficial graft-versus-leukemia effect. However, the introduction of foreign immune cells also carries a significant risk of triggering acute graft-versus-host disease.
Acute graft-versus-host disease occurs when donor-derived immune cells identify healthy recipient tissues and host protein structures as foreign targets, mounting an aggressive inflammatory attack. This immune reaction predominantly damages key organ systems, including the skin, liver, and gastrointestinal tract. Patients affected by severe forms of the condition suffer from painful tissue inflammation, significant organ dysfunction, and prolonged hospitalizations. Preventing this destructive immune response without compromising the therapeutic anti-tumor effect of the transplant remains a central challenge in modern clinical hematology.
Naturally occurring regulatory T cells function as essential controllers of the human immune system, responsible for maintaining self-tolerance and restraining excessive inflammatory reactions. While regulatory T cells possess the intrinsic biological capability to suppress harmful anti-recipient immune responses, their broad clinical application has historically been hindered by major technical limitations. Traditional methods required isolating these rare cells directly from the primary stem cell donor and expanding them in specialized cell culture laboratories over several weeks, a complex process that was unsuitable for urgent clinical use.
Current Diagnostic Standards and Immunosuppressive Management in Germany
Specialized university hospitals across Germany follow rigorous diagnostic and therapeutic protocols when preparing patients for allogeneic stem cell transplantation. Pre-transplant evaluations include exhaustive human leukocyte antigen typing, comprehensive organ function assessments, and detailed infectious disease screening to minimize procedural risks. High-resolution donor matching significantly reduces immunological barriers, yet it cannot completely eliminate the possibility of graft-versus-host complications. Consequently, continuous clinical monitoring and advanced laboratory diagnostics form the foundation of patient care before, during, and after stem cell infusion.
Standard preventive measures against graft-versus-host disease in German hematology centers rely heavily on combination drug regimens involving systemic immunosuppressive agents. Patients typically receive medications that inhibit donor T-cell proliferation and activation, starting prior to transplant infusion and continuing for several months. Although conventional immunosuppression substantially lowers the incidence of severe acute complications, it simultaneously weakens the recipient’s defenses against opportunist viral, bacterial, and fungal infections. Long-term pharmacotherapy may also impair the desirable graft-versus-tumor surveillance mechanism.
Post-transplant monitoring in German medical centers emphasizes early detection of subtle inflammatory signs affecting the skin, digestive system, or hepatic enzymes. When clinical symptoms of acute immune attack emerge, physicians must promptly escalate immunosuppressive therapy, often administering high-dose systemic corticosteroids. The medical community continues to seek targeted cell-based strategies that can induce specific immunological tolerance while avoiding the adverse effects associated with broad systemic immunosuppression.
The Innovative ATreg Methodology and Key Findings from Clinical Testing
The proprietary ATreg method developed by ActiTrexx GmbH in Mainz introduces a fundamental shift by activating regulatory T cells rather than expanding them over prolonged laboratory cultures. Regulatory T cells are isolated from the blood of healthy, third-party donors and stimulated with a patented activating agent for sixteen hours. Prof. Dr. Andrea Tüttenberg, Co-founder, Managing Director, and Chief Medical Officer of ActiTrexx GmbH, as well as researcher at the Hautklinik der Universitätsmedizin Mainz, explained that this short stimulation markedly enhances the natural tolerance-promoting capacity of the cells, allowing significantly lower cell numbers to achieve clinical efficacy.
A major advantage of this approach is that the cells do not need to originate from the primary stem cell donor. ATreg can be manufactured from standard blood donations provided by unrelated healthy volunteers and administered within twenty-four hours of processing. The Phase I/II trial, registered as ATreg-001 (EU CT number 2024-516599-14-00), was conducted across four German clinical sites: Universitätsmedizin Mainz under lead investigator Dr. E. M. Wagner-Drouet, Universitätsmedizin Dresden under Prof. Dr. M. Wermke, Universitätsklinikum Münster under Prof. Dr. M. Stelljes, and St.-Johannes-Hospital Dortmund under PD Dr. R. G. Meyer. The research received funding support from the Federal Ministry of Education and Research (BMBF) under the GO-Bio program and approval from the Paul-Ehrlich-Institut.
In the dose-escalation trial, ten patients received ATreg infusions approximately ten days after allogeneic stem cell transplantation alongside standard prophylactic medication. The results demonstrated an excellent safety profile, with no severe infusion-related adverse events or toxicities reported. All treated patients achieved successful stem cell engraftment, and no severe grade 3-4 acute graft-versus-host disease was observed during the 100-day post-transplant observation period. Furthermore, no transplant-related mortality occurred. Dr. Helmut Jonuleit, Co-founder, Chief Scientific Officer of ActiTrexx GmbH, inventor of the technology, and Research Director at the Hautklinik der Universitätsmedizin Mainz, noted that this milestone simplifies donor searches by reducing the necessity for complete genetic matching.
Significance for International Patients Seeking Specialized Care in Germany
The successful completion of this initial clinical trial represents a meaningful advancement in cell-based immunotherapies for stem cell recipients. By eliminating the necessity for multi-week laboratory cell expansion, the ATreg platform addresses one of the primary logistical bottlenecks in cellular medicine. ActiTrexx regards these early results as a strong positive foundation for further clinical evaluation, with plans underway to organize a randomized controlled follow-up study designed to compare ATreg directly against conventional prophylactic regimens in a larger patient cohort.
For international patients considering treatment for hematological conditions in Germany, it is important to recognize that the ATreg procedure remains an investigational therapy currently undergoing clinical evaluation. It is not yet part of routine standard care in hospital wards. Nevertheless, the successful implementation of such groundbreaking trials underscores the advanced scientific environment and clinical expertise available within German university medical centers.
When consulting with medical specialists regarding stem cell transplantation options in Germany, patients and their families are encouraged to discuss standard preventive protocols and current clinical advancements. Physicians at specialized university hospitals can offer detailed guidance regarding donor selection criteria, routine immunosuppressive management, and eligibility for ongoing clinical research studies. German medical institutions maintain rigorous quality standards to ensure patient safety across all stages of complex hematological treatment.
Source: Universitätsmedizin der Johannes Gutenberg-Universität Mainz